三阴性乳腺癌靶向信号通路最新研究进展  

Research Progress of Targeting Signal Pathway for Triple Negative Breast Cancer

作　　者：吴小红 杨嘉嘉[2] 罗宇飞 陈珂 张南文[1] WU Xiao-hong;YANG Jia-jia;LUO Yu-fei;CHEN Ke;ZHANG Nan-wen(School of Pharmacy,Fujian Medical University,Fuzhou 350122,China;Department of Ultrasound,Fujian Medical University Union Hospital,Fuzhou 350001,China;Department of Clinical Medicine,Fujian Medical University,Fuzhou 350122,China)

机构地区：[1]福建医科大学药学院,福州350122 [2]福建医科大学附属协和医院超声科,福州350001 [3]福建医科大学临床医学部,福州350122

出　　处：《海峡药学》2019年第4期1-3,共3页Strait Pharmaceutical Journal

基　　金：福建省卫生与计划生育委员会青年课题资助项目(编号:2015-1-41);福建医科大学大学生创新创业训练项目校级(编号:C18037)

摘　　要：三阴性乳腺癌约占所有乳腺癌类型的15%,年轻女性患者多见。三阴性乳腺癌的侵袭性很强,组织学分级高,易早期复发及远处转移,无病生存率和总生存率较低,预后比其他类型乳腺癌差,因此寻找TNBC靶向信号通路的有效靶点,以降低TNBC的早期复发和远处转移的发生率已成为近年研究的热点。Triple-negative breast cancer accounts for about 15%of all breast cancer types,more common in young women.Triple-negative breast cancer is highly invasive,with high histological grade,easy early recurrence and distant metastasis,low disease-free survival and overall survival,and poor prognosis compared to other types of breast cancer,so looking for TNBC targeted signaling pathway Effective targets to reduce the incidence of early recurrence and distant metastasis of TNBC have become hot spots in recent years.

关 键 词：三阴性乳腺癌 信号通路 酪氨酸激酶受体 促分裂原活化蛋白激酶 DNA损伤 

分 类 号：R965[医药卫生—药理学]